Identification of frequent activating HER2 mutations in primary canine pulmonary adenocarcinoma
G. Lorch, K. Sivaprakasam, V. Zismann, N. Perdigones, T. Contente-Cuomo, A. Nazareno, S. Facista, S. Wong, K. Drenner, W. S. Liang, J. M. Amann, S. L. Sinicropi-Yao, M. J. Koenig, K. La Perle, T. G. Whitsett, , W. P. D. Hendricks
This study identifies HER2 mutations in canine pulmonary adenocarcinomas, finding V659E mutations in 38% of cases and their association with drug sensitivity.
bioRxiv · Feb 25, 2019 · PreprintCancer Biology